Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of TP-3654 in Healthy Adults
NCT07492355Phase 1Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Mar 2024
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of nuvisertib in myelofibrosis (MF) (2 arms), sponsored by Sumitomo Pharma America. Primary endpoints: Maximum Observed Plasma Concentration at 13 days and Area Under the Curve at 13 days. Started Mar 2024; status: completed.
02
Drugs
nuvisertib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT07492355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07492355.